Uniform graft-versus-host disease prophylaxis using post-transplantation cyclophosphamide, methotrexate, and cyclosporine following peripheral blood hematopoietic stem cell transplantation from matched and haploidentical donors for transfusion-dependent thalassemia: a retrospective report from the BMF-WG of Hunan province, China

2024-9-1

Efficacy of Letermovir for CMV Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant.

2024-9-1

Racial and Ethnic Disparities in Autologous Hematopoietic Cell Transplant Utilization in Multiple Myeloma Have Persisted Over Time even after Referral to a Transplant Center

2024-9-1

Editorial Board

2024-9-1

Officers and Directors of ASTCT

2024-9-1

Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma

2024-9-1

The prevalence of pre-transplant frailty and mental distress in hematopoietic cell transplantation and association with clinical outcomes

2024-9-1

Effects of consolidation therapy with autologous hematopoietic stem cell transplantation after BCMA-CAR T-cell therapy on the survival of patients with relapsed or refractory multiple myeloma

2024-9-1

Impact of GVHD on relapse and non-relapse mortality following post-transplant cyclophosphamide-based transplantation

2024-9-1

ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome

2024-9-1

Levels of C-reactive protein and body temperature elevation during neutropenia predict engraftment and non-relapse mortality for unrelated single-unit cord blood transplantation in adults

2024-9-1

ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies

2024-9-1

Transplant Outcomes in Myelofibrosis: Impact of Donor Type [Cord Blood Grafts Supported by CD34+ selected Cells (Haplo-Cord) vs Matched Donors]

2024-9-1

Pre-admission Penicillin Allergy Evaluation Before Hematopoietic Stem Cell Transplantation Optimizes Febrile Neutropenia Treatment and Inpatient Resource Utilization

2024-9-1

Real World Application of Recently Proposed ASTCT/CIBMTR/ eBMT/ APBMT Consensus Risk Stratification for Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Children

2024-9-1

Proceedings of the 2024 Third Annual ASTCT-NMDP ACCESS Initiative Workshop

2024-9-1

Risk-Based Qualification of Cellular Starting Material Collection Sites: Tools to Determine Scope of Manufacturer Audits and Reduce Duplicative Efforts

2024-9-1

Differences in acute graft-versus-host disease (GVHD) severity and its outcomes between Black and White patients

2024-9-1

Masthead (Purpose and Scope)

2024-9-1

Table of Contents

2024-9-1

No Role for Tandem Autologous Stem Cell Transplantation in Modern Treatment Paradigms for Transplant Eligible Multiple Myeloma

2024-9-1

Myeloma CAR T-cell therapy toxicity timing: What is the right amount of post-treatment monitoring for our patients?

2024-8-23

Profile of a Pioneer: George W. Santos

2024-8-23

A Tool for the Assessment of HLA-DQ Heterodimer Variation in Hematopoietic Cell Transplantation

2024-8-1

Corrigendum to’ UM171 expansion of cord blood improves donor availability and HLA matching for all patients, including minorities’ [Transplantation and Cellular Therapy 28/7 (2022) 410-410

2024-8-1

Officers and Directors of ASTCT

2024-8-1

Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide

2024-8-1

Metagenomic Next-generation Sequencing in the Diagnosis of Pulmonary Infections After Allogeneic Hematopoietic Stem Cell Transplantation

2024-8-1

Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy

2024-8-1

Patients Beyond the Optimal Range of rATG-AUC Still Benefit from the Targeted Dosing Strategy in Unmanipulated Haplo-PBSCT

2024-8-1

Dynamic relapse prediction by peripheral blood WT1mRNA after allogeneic hematopoietic cell transplantation for myeloid neoplasms

2024-8-1

Outcomes of human leukocyte antigen-matched related donor and haploidentical allogeneic hematopoietic cell transplantation recipients by immune profiles of recipients and donors

2024-8-1

Application of the Harmonization Definition of Transplant Associated Thrombotic Microangiopathy (TA-TMA) requires a more expansive lens to accurately diagnose, and risk stratify patients- Beware Reliance on Schistocytes Alone

2024-8-1

ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies

2024-8-1

Total Body Irradiation and Fludarabine with Post-Transplant Cyclophosphamide for Mismatched Related or Unrelated Donor HCT

2024-8-1

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma Immunotherapy Consortium Real World Experience

2024-8-1

Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation

2024-8-1

Multiplexed Gastrointestinal PCR Panels for the Evaluation of Diarrhea in Hematopoietic Stem Cell Transplantation Recipients

2024-8-1

Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive Chemomobilization

2024-8-1

Model-Based Antithymocyte Globulin in αβhaplo-Hematopoietic Stem Cell Transplantation Facilitates Engraftment, Expedites T Cell Recovery, and Mitigates the Risk of Acute Graft-versus-Host Disease

2024-8-1

COMPARISON OF THREE STRATEGIES OF GVHD PROPHYLAXIS AFTER T-CELL REPLETE HAPLOIDENTICAL HEMATOPOIETIC TRANSPLANTATION: TACROLIMUS vs. CALCINEURIN INHIBITORS-MMF vs. SIROLIMUS-MMF

2024-8-1

The Clinical Influence of Complete Remission With Incomplete Count Recovery (CRi) on Single-Unit Unrelated Cord Blood Transplantation in Patients With Acute Leukemia

2024-8-1

Surrogates of endothelial injury predict survival after post-transplant cyclophosphamide

2024-8-1

Design and Development of a Multimodal Digital Intervention (SHIFT App) to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant (HSCT) Survivors

2024-8-1

A Retrospective Study of Pediatric Patients with Low- or Intermediate-risk Acute Myeloid Leukemia who Underwent Allogeneic Hematopoietic Cell Transplantation for the AML-05 Study Conducted by the Japanese Pediatric Leukemia/Lymphoma Study Group

2024-8-1

Early Toxicity and Efficacy of Four Different Conditioning Regimens for Autologous Hematopoietic Cell Transplantation in Patients With Lymphoma: Impact of Drug Shortages in a Resource-Constrained Country

2024-8-1

COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics

2024-8-1

CAST Regimen for GvHD Prophylaxis: A CIBMTR Propensity Score-Matched Analysis

2024-8-1

Table of Contents

2024-8-1

Masthead (Purpose and Scope)

2024-8-1